ABSTRACT Hypoactive sexual desire disorder (HSDD) represents a common condition among transgender women. However, to date no specific guidelines for the management of HSDD in transgender

persons are available. The aim of the present narrative Review is to evaluate evidence-based treatment for HSDD and to suggest treatment options for HSDD in transgender women. Clinically

relevant publications on the management of HSDD (from 1985 to 2020) were searched in PubMed and Medline databases, using the following terms: “sexual desire”, “sexual health”, “HSDD”,

“transgender”, “gender-affirming treatment”, “sexual therapy”, “testosterone treatment”, “Central nervous system-active medications”, and variants. Since sexual desire could be affected by

bremelanotide, bupropion and buspirone—and transdermal testosterone, bearing in mind that this option could be poorly accepted by patients due to the risk of virilizing effects. The lack of

data regarding the efficacy of HSDD treatment options in transgender women emphasize the need for literature to focus more on this topic in the future. Access through your institution Buy or

subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online

access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which

are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS

THE CLINICAL MANAGEMENT OF TESTOSTERONE REPLACEMENT THERAPY IN POSTMENOPAUSAL WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER: A REVIEW Article Open access 05 October 2022 A CLINICAL GUIDE TO

RARE MALE SEXUAL DISORDERS Article 05 September 2023 AN INTEGRATED MODEL TO ASSESS AND TREAT COMPULSIVE SEXUAL BEHAVIOUR DISORDER Article 19 June 2020 REFERENCES * American Psychiatric

Association. Diagnostic and statistical manual of mental disorders. 5th edition. Washington DC: American Psychiatric Association; 2013. Book  Google Scholar  * Ristori J, Cocchetti C,

Castellini G, Pierdominici M, Cipriani A, Testi D, et al. Hormonal treatment effect on sexual distress in transgender persons: 2-year follow-up data. J Sex Med. 2020;17:142–51. Article  CAS

  PubMed  Google Scholar  * Kussin-Shoptaw AL, Fletcher JB, Reback CJ. Physical and/or sexual abuse is associated with increased psychological and emotional distress among transgender women.

LGBT Health. 2017;4:268–74. Article  PubMed  PubMed Central  Google Scholar  * Nikkelen SWC, Kreukels BPC. Sexual experiences in transgender people: the role of desire for gender-confirming

interventions, psychological well-being, and body satisfaction. J Sex Marital Ther. 2018;44:370–81. Article  PubMed  Google Scholar  * Defreyne J, Elaut E, Kreukels B, Fisher AD, Castellini

G, Staphorsius A, et al. Sexual desire changes in transgender individuals upon initiation of hormone treatment: results from the longitudinal European Network for the Investigation of

Gender Incongruence. J Sex Med. 2020;17:812–25. Article  CAS  PubMed  Google Scholar  * Bartolucci C, Gómez-Gil E, Salamero M, Esteva I, Guillamon A, Zubiaurre L, et al. Sexual quality of

life in gender dysphoric adults before genital sex reassignment surgery. J Sex Med. 2015;12:180–8. Article  PubMed  Google Scholar  * Selvaggi G, Monstrey S, Ceulemans P, T’Sjoen G, De

Cuypere G, Hoebeke P. Genital sensitivity after sex reassignment surgery in transsexual patients. Ann Plast Surg. 2007;58:427–33. Article  CAS  PubMed  Google Scholar  * De Cuypere G,

T’Sjoen G, Beerten R, Selvaggi G, De Sutter P, Hoebeke P, et al. Sexual and physical health after sex reassignment surgery. Arch Sex Behav. 2005;34:679–90. Article  PubMed  Google Scholar  *

T’Sjoen G, Arcelus J, De Vries ALC, Fisher AD, Nieder TO, Özer M, et al. European society for sexual medicine position statement “Assessment and Hormonal Management in Adolescent and Adult

Trans People, With Attention for Sexual Function and Satisfaction”. J Sex Med. 2020;17:570–84. Article  PubMed  Google Scholar  * Wierckx K, Elaut E, Van Hoorde B, Heylens G, De Cuypere G,

Monstrey S, et al. Sexual desire in trans persons: associations with sex reassignment treatment. J Sex Med. 2014;11:107–18. Article  PubMed  Google Scholar  * Elaut E, De Cuypere G, De

Sutter P, Gijs L, Van Trotsenburg M, Heylens G, et al. Hypoactive sexual desire in transsexual women: prevalence and association with testosterone levels. Eur J Endocrinol. 2008;158:393–9.

Article  CAS  PubMed  Google Scholar  * American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Washington DC: American Psychiatric Association;

1994. Google Scholar  * McCabe MP, Sharlip ID, Atalla E, Balon R, Fisher AD, Laumann E, et al. Definitions of sexual dysfunctions in women and men: a consensus statement from the fourth

international consultation on sexual medicine 2015. J Sex Med. 2016;13:135–43. Article  PubMed  Google Scholar  * Kerckhof ME, Kreukels BPC, Nieder TO, Becker-Hébly I, van de Grift TC,

Staphorsius AS, et al. prevalence of sexual dysfunctions in transgender persons: results from the ENIGI follow-up study. J Sex Med. 2019;16:2018–29. Article  PubMed  Google Scholar  * Rosen

RC, Shifren JL, Monz BU, Odom DM, Russo PA, Johannes CB. Correlates of sexually related personal distress in women with low sexual desire. J Sex Med. 2009;6:1549–60. Article  PubMed  Google

Scholar  * Leiblum SR, Koochaki PE, Rodenberg CA, Barton IP, Rosen RC. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women’s International Study of Health

and Sexuality (WISHeS). Menopause. 2006;13:46–56. Article  PubMed  Google Scholar  * Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E, et al. Sexual problems among women and

men aged 40–80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res. 2005;17:39–57. Article  CAS  PubMed  Google Scholar  * Clayton

AH, Goldstein I, Kim NN, Althof SE, Faubion SS, Faught BM, et al. The international society for the Study of Women’s Sexual health process of care for management of hypoactive sexual desire

disorder in women. Mayo Clin Proc. 2018;93:467–87. Article  PubMed  Google Scholar  * Fisher AD, Castellini G, Bandini E, Casale H, Fanni E, Benni L, et al. Cross-sex hormonal treatment and

body uneasiness in individuals with gender dysphoria. J Sex Med. 2014;11:709–19. Article  CAS  PubMed  Google Scholar  * Murad MH, Elamin MB, Garcia MZ, Mullan RJ, Murad A, Erwin PJ, et al.

Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. Clin Endocrinol. 2010;72:214–31. Article  Google Scholar  * van de

Grift TC, Elaut E, Cerwenka SC, Cohen-Kettenis PT, De Cuypere G, Richter-Appelt H, et al. Effects of medical interventions on gender dysphoria and body image: a follow-up study. Psychosom

Med. 2017;79:815–23. Article  PubMed  PubMed Central  Google Scholar  * Holmberg M, Arver S, Dhejne C. Supporting sexuality and improving sexual function in transgender persons. Nat Rev

Urol. 2019;16:121–39. Article  CAS  PubMed  Google Scholar  * Dhejne C, Van Vlerken R, Heylens G, Arcelus J. Mental health and gender dysphoria: a review of the literature. Int Rev

Psychiatry. 2016;28:44–57. Article  PubMed  Google Scholar  * Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol.

2009;29:259–66. Article  CAS  PubMed  Google Scholar  * Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for managing sexual dysfunction induced by

antidepressant medication. Cochrane Database Syst Rev. 2013;5:CD003382. * Defreyne J, Nota N, Pereira C, Schreiner T, Fisher AD, den Heijer M, et al. Transient elevated serum prolactin in

trans women is caused by cyproterone acetate treatment. LGBT Health. 2017;4:328–36. Article  PubMed  Google Scholar  * Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad

MH, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;102:3869–903. Article  PubMed 

Google Scholar  * Corona G, Mannucci E, Fisher AD, Lotti F, Ricca V, Balercia G, et al. Effect of hyperprolactinemia in male patients consulting for sexual dysfunction. J Sex Med.

2007;4:1485–93. Article  CAS  PubMed  Google Scholar  * Sigurjonsson H, Rinder J, Möllermark C, Farnebo F, Lundgren T. Male to female gender reassignment surgery: surgical outcomes of

consecutive patients during 14 years. JPRAS Open. 2015;6:69–73. Article  Google Scholar  * Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, et al. Efficacy of intravaginal

dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause.

2018;25:1339–53. Article  PubMed  Google Scholar  * Unger CA. Update on gender- affirming treatment for the transgender woman. Semin Reprod Med. 2017;35:442–7. Article  PubMed  Google

Scholar  * Brotto LA, Basson R, Carlson M, Zhu C. Impact of an integrated mindfulness and cognitive behavioural treatment for provoked vestibulodynia (IMPROVED): a qualitative study. Sex

Relat Ther. 2013;28:3–19. Article  Google Scholar  * Brotto LA, Basson R, Luria M. A mindfulness-based group psychoeducational intervention targeting sexual arousal disorder in women. J Sex

Med. 2008;5:1646–59. Article  PubMed  Google Scholar  * Frühauf S, Gerger H, Schmidt HM, Munder T, Barth J. Efficacy of psychological interventions for sexual dysfunction: a systematic

review and meta-analysis. Arch Sex Behav. 2013;42:915–33. Article  PubMed  Google Scholar  * Silverstein RG, Brown AC, Roth HD, Britton WB. Effects of mindfulness training on body awareness

to sexual stimuli: implications for female sexual dysfunction. Psychosom Med. 2011;73:817–25. Article  PubMed  PubMed Central  Google Scholar  * Brotto LA, Basson R. Group mindfulness-based

therapy significantly improves sexual desire in women. Behav Res Ther. 2014;57:43–54. Article  PubMed  Google Scholar  * Gunst A, Ventus D, Arver S, Dhejne C, Jern P. A randomized, wait

list-controlled trial suggests that two psychobehavioral interventions are effective for women’s hypoactive sexual desire. Elsevier. 2018. * Gelman F, Atrio J. Flibanserin for hypoactive

sexual desire disorder: place in therapy. Ther Adv Chronic Dis. 2017;8:16–25. Article  CAS  PubMed  PubMed Central  Google Scholar  * Katz M, Derogatis LR, Ackerman R, Hedges P, Lesko L,

Garcia M Jr, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med. 2013;10:1807–15. Article  CAS  PubMed  Google Scholar

  * Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia M Jr, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J

Sex Med. 2012;9:793–804. Article  CAS  PubMed  Google Scholar  * Derogatis LR, Komer L, Katz M, Moreau M, Kimura T, Garcia M Jr, et al. Treatment of hypoactive sexual desire disorder in

premenopausal women: efficacy of flibanserin in the VIOLET Study. J Sex Med. 2012;9:1074–85. Article  CAS  PubMed  Google Scholar  * Dhillon S, Keam SJ. Bremelanotide: first approval. Drugs.

2019;79:1599–606. Article  PubMed  Google Scholar  * Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the treatment of hypoactive sexual desire

disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134:899–908. Article  CAS  PubMed  PubMed Central  Google Scholar  * Livingstone-Banks J, Norris E, Hartmann-Boyce J, West R,

Jarvis M, Hajek P. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev. 2019;2:CD003999. PubMed  Google Scholar  * Segraves RT, Clayton A, Croft H, Wolf A,

Warnock J. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J Clin Psychopharmacol. 2004;24:339–42. Article  CAS  PubMed  Google

Scholar  * Safarinejad MR, Hosseini SY, Asgari MA, Dadkhah AT. A randomized, double-blind, placebo-controlled study of the efficacy and safety of buproprion for treating hypoactive sexual

desire disorder in ovulating women. BJU Int. 2020;106:832–9. Article  Google Scholar  * Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for

generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019;393:768–77. Article  CAS  PubMed  Google Scholar  * Landén M, Eriksson E, Agren H, Fahlén T. Effect

of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1999;19:268–71. Article  PubMed  Google Scholar  *

Newton RE, Marunycz JD, Alderdice MT, Napoliello MJ. Review of the side-effect profile of buspirone. Am J Med. 1986;80:17–21. Article  CAS  PubMed  Google Scholar  * Braunstein GD, Sundwall

DA, Katz M. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch

Intern Med. 2005;165:1582–9. Article  CAS  PubMed  Google Scholar  * Buster JE, Kingsberg SA, Aguirre O. Testosterone patch for low sexual desire in surgically menopausal women: a randomized

trial. Obstet Gynecol. 2005;105:944–52. Article  CAS  PubMed  Google Scholar  * Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, et al. Testosterone patch increases sexual

activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab. 2005;90:5226–33. Article  CAS  PubMed  Google Scholar  * Davis SR, van der

Mooren MJ, van Lunsen RH. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled

trial. Menopause. 2006;13:387–96. Article  PubMed  Google Scholar  * Shifren JL, Davis SR, Moreau M. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally

menopausal women: results from the INTIMATE NM1 study. Menopause. 2006;13:770–9. Article  PubMed  Google Scholar  * Davis SR, Braunstein GD. Efficacy and safety of testosterone in the

management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med. 2012;9:1134–48. Article  CAS  PubMed  Google Scholar  * Panay N, Al-Azzawi F, Bouchard C. Testosterone

treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric. 2010;13:121–31. Article  CAS  PubMed  Google Scholar  * Waldman T, Shufelt CL, Braunstein GD. Safety and

efficacy of transdermal testosterone for treatment of hypoactive sexual desire disorder. Clin Invest. 2012;2:423–32. Article  CAS  Google Scholar  * Herold DA, Fitzgerald RL. Immunoassays

for testosterone in women: better than a guess? Clin Chem. 2003;49:1250–1. Article  CAS  PubMed  Google Scholar  * Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH, et al.

Androgen therapy in women: a reappraisal; an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3489–510. Article  CAS  PubMed  Google Scholar  * Davis SR,

Moreau M, Kroll R, Bouchard C, Panay N, Gass M, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008;359:2005–17. Article  CAS  PubMed  Google

Scholar  * Nachtigall L, Casson P, Lucas J, Schofield V, Melson C, Simon JA. Safety and tolerabililty of testosterone patch therapy for up to 4 years in surgically menopausal women receiving

oral or transdermal oestrogen. Gynecol Endocrinol. 2011;27:39–48. Article  CAS  PubMed  Google Scholar  * Dimitrakakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in

postmenopausal women using testosterone in addition to usual hormone therapy. Menopause. 2004;11:531–5. Article  PubMed  Google Scholar  * Kronawitter D, Gooren LJ, Zollver H, Oppelt PG,

Beckmann MW, Dittrich R, et al. Effects of transdermal testosterone or oral dydrogesterone on hypoactive sexual desire disorder in transsexual women: results of a pilot study. Eur J

Endocrinol. 2009;161:363–8. Article  CAS  PubMed  Google Scholar  * Poels S, Bloemers J, van Rooij K. Toward personalized sexual medicine (part 2): testosterone combined with a PDE5

inhibitor increases sexual satisfaction in women with HSDD and FSAD, and a low sensitive system for sexual cues. J Sex Med. 2013;10:810–23. Article  CAS  PubMed  Google Scholar  * van Rooij

K, Poels S, Bloemers J. Toward personalized sexual medicine (part 3): testosterone combined with a serotonin1A receptor agonist increases sexual satisfaction in women with HSDD and FSAD, and

dysfunctional activation of sexual inhibitory mechanisms. J Sex Med. 2013;10:824–37. Article  PubMed  Google Scholar  * Maseroli E, Santangelo A, Lara-Fontes B, Quintana GR, Mac Cionnaith

CE, Casarrubea M, et al. The non-aromatizable androgen dihydrotestosterone (DHT) facilitates sexual behavior in ovariectomized female rats primed with estradiol. Psychoneuroendocrinology.

2020; https://doi.org/10.1016/j.psyneuen.2020.104606. * Dören M, Rubig A, Coelingh Bennink HJ, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with

tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril. 2001;75:554–9. Article  PubMed  Google Scholar  * Labrie F, Archer DF, Koltun W,

Vachon A, Young D, Frenette L, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of

the genitourinary syndrome of menopause. Menopause. 2016;23:243–56. Article  PubMed  Google Scholar  * Nastri CO, Lara LA, Ferriani RA, Rosa-E-Silva AC, Figueiredo JB, Martins WP. Hormone

therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2013;6:CD009672. * Elraiyah T, Sonbol MB, Wang Z, Khairalseed T, Asi N, Undavalli C, et

al. The benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab.

2014;99:3536–42. Article  CAS  PubMed  PubMed Central  Google Scholar  * Jesmin S, Mowa CN, Matsuda N, Salah-Eldin AE, Togashi H, Sakuma I, et al. Evidence for a potential role of estrogen

in the penis: detection of estrogen receptor-alpha and -beta messenger ribonucleic acid and protein. Endocrinology. 2002;143:4764–74. Article  CAS  PubMed  Google Scholar  * Bergink EW,

Janssen PS, Turpijn EW, van der Vies J. Comparison of the receptor binding properties of nandrolone and testosterone under in vitro and in vivo conditions. J Steroid Biochem. 1985;22:831–6.

Article  CAS  PubMed  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University

Hospital, Viale Pieraccini 6, 50139, Florence, Italy Carlotta Cocchetti, Jiska Ristori, Francesca Mazzoli, Linda Vignozzi & Alessandra Daphne Fisher * Department of Experimental,

Clinical and Biomedical Sciences, Careggi University Hospital, Viale Pieraccini 6, 50139, Florence, Italy Mario Maggi Authors * Carlotta Cocchetti View author publications You can also

search for this author inPubMed Google Scholar * Jiska Ristori View author publications You can also search for this author inPubMed Google Scholar * Francesca Mazzoli View author

publications You can also search for this author inPubMed Google Scholar * Linda Vignozzi View author publications You can also search for this author inPubMed Google Scholar * Mario Maggi

View author publications You can also search for this author inPubMed Google Scholar * Alessandra Daphne Fisher View author publications You can also search for this author inPubMed Google

Scholar CORRESPONDING AUTHOR Correspondence to Alessandra Daphne Fisher. ETHICS DECLARATIONS CONFLICT OF INTEREST The authors declare that they have no conflict of interest. ADDITIONAL

INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. RIGHTS AND PERMISSIONS Reprints and

permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Cocchetti, C., Ristori, J., Mazzoli, F. _et al._ Management of hypoactive sexual desire disorder in transgender women: a guide for

clinicians. _Int J Impot Res_ 33, 703–709 (2021). https://doi.org/10.1038/s41443-021-00409-8 Download citation * Received: 27 April 2020 * Revised: 29 December 2020 * Accepted: 12 January

2021 * Published: 08 February 2021 * Issue Date: November 2021 * DOI: https://doi.org/10.1038/s41443-021-00409-8 SHARE THIS ARTICLE Anyone you share the following link with will be able to

read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing

initiative